Innate Pharma SA

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

LOS ANGELES--(BUSINESS WIRE)---- $IPHA #IPHA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses of $100,000 to Contact the Firm

Milestone payment further bolsters Innate's cash position

First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca

Atlanta, Georgia--(Newsfile Corp. - October 22, 2020) - Holzer & Holzer, LLC is investigating whether Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA) complied with federal securities laws. On September 8, 2020, the Company announced it had agreed to amend a previously negotiated agreement with AstraZeneca. The price of Innate's stock fell following the announcement. If you purchased shares of Innate and suffered a loss on that investment, you are encouraged to contact...

SHAREHOLDER ALERT: Investigation of Innate Pharma Announced by Holzer & Holzer, LLC

LOS ANGELES--(BUSINESS WIRE)---- $IPHA #IPHA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A.

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Innate Pharma S.A. (NASDAQ: IPHA) resulting from allegations that Innate may have issued materially misleading business information to the investing public. On October 23, 2018, Innate announced its long-term strategic partnership with AstraZeneca, which in part would include a payment to Innate of $100 million in milestone payments

IPHA LOSS NOTICE: Rosen Law Firm Announces Investigation of Securities Claims Against Innate Pharma S.A – IPHA

MARSEILLE, France, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at October 1, 2020:

Number of Shares and Voting Rights of Innate Pharma as of October 1, 2020

MARSEILLE, France, Sept.  08, 2020  (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2020. The consolidated financial statements are attached to this press release.

Innate Pharma Reports First Half 2020 Financial Results and Business Update

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announces that it plans to participate in the following upcoming virtual investor conferences in September 2020:

Upcoming investor conferences

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as at August 1, 2020:

Number of shares and voting rights of Innate Pharma as at August 1, 2020

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the Company has obtained funding of €6.8M under the PSPC-COVID call for projects to support the Company’s COVID-19 research and development activities. This initiative is operated on behalf of the State by Bpifrance as part of the Programme d’investissements d’avenir (PIA), led by the Secrétariat général pour l’investissement (SGPI). 

Innate Pharma obtains €6.8M in public funding for its COVID-19 research and development activities

New research suggests targeting C5a-C5aR1 axis could limit severe inflammatory response

INNATE PHARMA ANNOUNCES PUBLICATION OF EXPLORE COVID-19 TRANSLATIONAL STUDY FINDINGS IN NATURE

Pierre Dodion, MD retires as Chief Medical Officer

Innate Pharma announces the appointment of Joyson Karakunnel, MD, MSC, FACP as Chief Medical Officer

Innate Pharma to re-activate TELLOMAK trial in the US

U.S. Food and Drug Administration  Lifts Partial Clinical Hold on Lacutamab TELLOMAK Trial in Advanced T-Cell Lymphomas

U.S. Food and Drug Administration lifts partial clinical hold on lacutamab TELLOMAK trial in advanced T-cell lymphomas

Bayer AG

InflaRx

Europe stocks rally on hopes that the European Union will unveil large stimulus package to reduce the economic fallout from the coronavirus pandemic.

Europe Equities Are Hot on Stimulus Optimism: 5 Picks

Pascale Boissel appointed new member of Innate’s Supervisory Board Pascale Boissel appointed new member of Innate’s Supervisory Board

Outcome Of Annual General Meeting Of  May 19, 2020

Pascale Boissel appointed new member of Innate’s Supervisory    Board

Outcome of Annual General Meeting of May 19, 2020

Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rate

Innate Pharma to Present New Efficacy Data For Monalizumab in Combination With Cetuximab in Head And Neck cancer at The ASCO20 Virtual Scientific Progral

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) today announced its revenue and cash position for the three-month period ended March 31, 2020.

Innate Pharma First  Quarter  2020  Report

MARSEILLE, France, May  12, 2020  (GLOBE NEWSWIRE) -- Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) today announced its revenue and cash position for the three-month period ended March 31, 2020.

Innate Pharma First Quarter 2020 Report

MARSEILLE, France, May  06, 2020  (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter, Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as at May 1, 2020:

Number of Shares and Voting Rights  of Innate Pharma as at May 1, 2020

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter, Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as at May 1, 2020:

Number of Shares and Voting Rights of Innate Pharma as at May 1, 2020

Initial  translational analysis, EXPLORE, showed overexpression of C5a/C5aR pathway in patients with severe COVID-19

First patient dosed in avdoralimab  Phase II clinical trial in COVID-19 patients with severe pneumonia

Initial translational analysis, EXPLORE, showed overexpression of C5a/C5aR pathway in patients with severe COVID-19 Initial translational analysis, EXPLORE, showed overexpression of C5a/C5aR pathway in patients with severe COVID-19

First Patient Dosed in Avdoralimab Phase II Clinical Trial in COVID-19 Patients With Severe Pneumonia

MARSEILLE, France, April  24, 2020  (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2019 Universal Registration Document (Document d’enregistrement universel) for the year ended December 31, 2019 with the French market authority “Autorité des Marchés Financiers” (“AMF”). It can be consulted and downloaded (in French) on the Company’s website ( https://investors.innate-pharma.com/regulated-information/financial-reports ) and on the AMF’s website (www.amf-france.org).

News for Innate Pharma SA Stock (IPHA)